Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European Lung Cancer Congress 2019 /
ALK-positive NSCLC: Treatments and latest developments

10th - 13th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.04.19
Views: 2297

Prof Tony Mok - Chinese University of Hong Kong, Hong Kong

Prof Tony Mok speaks to ecancer at the European Lung Cancer Congress 2019 about the treatment of ALK-positive non-small-cell lung cancer (NSCLC) using ALK inhibitors.

Prof Mok discusses the effectiveness of second-generation ALK inhibitors compared to first-generation inhibitor (e.g. alectinib or brigatinib vs. crizotinib). He also mentions there is now a tendency to administer these second-generation ALK inhibitors in the first-line setting.

Prof Mok also explains how immunohistochemistry (IHC) is now commonly used to identify ALK translocations among patients in both the ALEX study and in the clinic. 

He also describes the challenges in the diagnosis of ALK-positive NSCLC patients, which include insufficient tumour tissue for fluorescence in situ hybridisation (FISH) or IHC testing. To avoid this, Prof Mok explains an upcoming study called B-F1RST which will assess the use of a liquid biopsy to identify patients with the ALK translocation.

In regard to managing brain metastases in these patients, Prof Mok believes we must study these patients further to determine those that will benefit from systemic therapy or radiotherapy.

Due to the diversity in mutations among ALK-positive patients, resistance is another challenge - in which Prof Mok believes therapy selection in the future should depend on the patient's pattern of resistance.

Prof Mok describes the methodology and results of the global ALEX trial - which was the second study to confirm the efficacy of alectinib compared to crizotinib.

Challenges surrounding the diagnosis and treatment of ALK-positive NSCLC
Highlights from the ALEX clinical trial study
Current clinical landscape for ALK-positive NSCLC patients


This programme has been supported by Roche.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation